Capricor Therapeutics (NASDAQ: CAPR) shares are up 30% after the company said the U.S. FDA has indicated it is willing to accept the company’s proposal to use the Performance of the Upper Limb as the basis for the primary efficacy endpoint for clinical studies of CAP-1002 for the treatment of muscular dystrophy. Official minutes from the company’s recent meeting with the regulatory agency also show support for submission of an Investigational New Drug (IND) application to clinically evaluate repeat intravenous administration of CAP-1002. “The FDA’s response to our proposed clinical development plan supports our near-term objective of submitting an IND for intravenous CAP-1002 as well as provides us with clarity on a path to potential product registration,” Capricor president and CEO Linda Marbán, Ph.D., stated in the news release.
To view the full press release, visit: http://nnw.fm/EcdF4
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company developing first-in-class biological therapies. Capricor’s lead candidate, CAP-1002, is a cell-based candidate currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor is also exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders. For more information, visit www.capricor.com.
More from NetworkNewsBreaks
SeeThruEquity Initiates Coverage on Alternate Health Corp. (AHGIF)
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
